

SEP 7 - 2007

PATENT
Docket No. 265.0045 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Hamill et al.)	Group Art Unit: 1642
)	
Serial No.: 10/585,503)	Examiner: Unknown
Confirmation No.: 2236)	
Filed: 17 January 2007)	
)	
For: MECHANOSENSITIVE ION CHANNELS AND METHODS OF USE		

FACSIMILE TRANSMISSION TO THE PTO

Commissioner for Patents
Mail Stop PGPUB
P.O. Box 1450
Alexandria, VA 22313-1450

FAX NUMBER: (571) 273-8300
Total Pages (including cover page): 9
Time: 2:56 pm (Central Time)
(Transmission must be complete by
midnight eastern time.)

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission: Request for Correction of Patent Application Publication (1 page); Errors on Published Application (1 page); copies of relevant pages from Application as filed, Application Data Sheet, and published Application (6 pgs. total)

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Mueting, Raasch & Gebhardt, P.A.
Customer Number: 26813

September 7, 2007
Date

By: David L. Provence
David L. Provence
Reg. No. 43,022
Direct Dial (612)305-1005

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to the Commissioner for Patents, Mail Stop PGPUB, P.O. Box 1450, Alexandria, VA 22313-1450, on this 7th day of September, 2007, at 2:56 pm (Central Time).

September 7, 2007
Date

Signature: Dani Morey
Name: Dani Morey

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

SEP 7 - 2007

PATENT
Docket No. 265.0045 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Hamill et al.)	Group Art Unit:	1642
)		
Serial No.:	10/585,503)	Examiner:	Unknown
Confirmation No.:	2236)		
Filed:	17 January 2007)		

For: MECHANOSENSITIVE ION CHANNELS AND METHODS OF USE
 Patent Application Publication No.: US 2007/0190600 A1

REQUEST FOR CORRECTION OF PATENT APPLICATION PUBLICATION

Mail Stop PGPUB
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

This paper is a request for correction and republication of the above-identified Patent Application Publication, which was published on 16 August 2007.

Applicant's Representatives identified the following errors made by the U.S. Patent and Trademark Office: typographical errors. The errors are indicated on the form entitled "Errors on Published Application" included herewith.

Pursuant to 37 C.F.R. §1.221(b), we request that the error(s) indicated above be corrected, and that the above-identified Patent Application Publication be re-published without additional publication or processing fees.

CERTIFICATE UNDER 37 C.F.R. 1.8:	
<p>The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to: Mail Stop PGPUB, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this <u>24</u> day of <u>September</u>, 2007, at <u>2:56 pm</u> (Central Time).</p> <p>By: <u>Dani Moroz</u> Name: <u>Dani Moroz</u></p>	

Respectfully submitted
 By
 Mueting, Raasch & Gebhardt, P.A.
 P.O. Box 581415
 Minneapolis, MN 55458-1415
 Phone: (612)305-1220
 Facsimile: (612)305-1228
 Customer Number 26813

September 7, 2007
 Date

By: David L. Provence
 David L. Provence
 Reg. No. 43,022
 Direct Dial (612)305-1005

SEP 7 - 2007

Errors on Published Application

File No. 265,0045 0101Inventor: Hamill et al.Serial No. 10/585,503Filed: 17 January 2007Confirmation No. 22336Proofreader's Initials: dmnApplication Publication Date: 16 August 2007

Published Application Page/Col.	Line #	Application as Filed Page	Line #	Error Fault	Correction
Face page		Application Data Sheet		PTO	Inventor Maroto should be Maroto
Page 23, Col. 1 (claim 12)	14	48	14	PTO	decrease should be decreases
Page 23, Col. 1 (claim 14)	21	48	21	PTO	polypeptides should be polypeptide
Page 23, Col. 1 (claim 19)	30	48	34	PTO	identifies should be identified
Page 23, Col. 1 (claim 21)	41	49	2	PTO	After "amount" insert --of a composition comprising an agent that decreases activity of a--
Page 23, Col. 1 (claim 25)	56	49	24	PTO	After "comprising SEQ ID NO:" insert --1--.
Page 23, Col. 1 (claim 25)	56	49	24	PTO	Delete "to"
Page 23, Col. 1 (claim 26)	57	49	26	PTO	Delete "The method of claim 24 wherein the agent is a polypeptide comprising SEQ ID NO: 1 or SEQ ID NO:7." and insert --The method of claim 23 wherein the agent is an antibody that specifically binds an MscCa polypeptide.--
Page 23, Col. 2 (claim 31)	27	50	22	PTO	RNS should be RNA
Page 23, Col. 2 (claim 32)	33	50	27	PTO	comprise should be comprises



US 20070190600A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2007/0190600 A1
(43) Pub. Date: Aug. 16, 2007
Hamill et al.(54) MECHANOSENSITIVE ION CHANNELS AND
METHODS OF USE

Related U.S. Application Data

(60) Provisional application No. 60/535,327, filed on Jan.
9, 2004.(75) Inventors: Owen P. Hamill, Galveston, TX (US);
Rosario Marato, Galveston, TX (US)

Publication Classification

Correspondence Address:
MUETING, RAASCH & GEBHARDT, P.A.
P.O. BOX 581415
MINNEAPOLIS, MN 55458 (US)(51) Int. Cl.
C07K 14/705 (2006.01)
C07H 21/04 (2006.01)
C12P 21/06 (2006.01)
(52) U.S. Cl. 435/69.1; 435/320.1; 435/325;
530/350; 536/23.5(73) Assignee: Board of Regents, The University of
Texas System, Austin, TX (US)

ABSTRACT

(21) Appl. No.: 10/585,503

The present invention provides methods for identifying
agents that decrease the activity of a mechanosensitive ion
channels, preferably, a mechanosensitive Ca^{2+} -permeable
channel (MscCa) channel. The present invention also pro-
vides methods for using agents that decrease the activity of
mechanosensitive ion channels, including, for instance, meth-
ods for treating cancer, methods for decreasing metastasis of
a cancer cell, and methods for decreasing a symptom asso-
ciated with cancer.

(22) PCT Filed: Jan. 10, 2005

(86) PCT No.: PCT/US05/00722

§ 371(c)(1).
(2), (4) Date: Jan. 17, 2007

US 2007/0190600 A1

Aug. 16, 2007

23

11. An agent identified by the method of claim 1.

12. A method for identifying an agent that decreases a phenotype of a cell comprising:

contacting a cell expressing an MscCa channel with a candidate agent to yield a treated cell; and

comparing the phenotype of the treated cell with the phenotype of a control cell not contacted with the candidate agent, wherein the phenotype is selected from the group of motility, invasiveness, proliferation, and a combination thereof, and wherein a decreased phenotype for the treated cell indicates the candidate agent decreases the phenotype.

13. The method of claim 12 wherein the candidate agent causes activity of an MscCa channel of the treated cell to decrease.

14. The method of claim 12 wherein the MscCa channel comprises a polypeptide comprising an amino acid sequence of at least 90% identity to SEQ ID NO: 2, wherein the polypeptides has MscCa activity.

15. The method of claim 14 wherein the MscCa channel comprises a polypeptide comprising SEQ ID NO: 2.

16. The method of claim 12 wherein the cell is a tumor cell.

17. The method of claim 12 wherein the cell is a human prostate tumor cell line.

18. The method of claim 17 wherein the human prostate tumor cell line is ATCC CRL-1435.

19. An agent identifies by the method of claim 12.

20. A method for treating cancer comprising:

administering to a subject having cancer an effective amount of a composition comprising an agent that decreases activity of a mechanosensitive ion channel present on a cancer cell, wherein a symptom of the cancer is decreased.

21. A method for decreasing metastasis of a cancer cell comprising:

administering to a subject at risk of developing cancer an effective amount mechanosensitive ion channel.

22. A method for decreasing a symptom associated with cancer comprising:

administering to a subject having cancer an effective amount of a composition comprising an agent that decreases activity of a mechanosensitive ion channel.

23. The method of claim 20, 21, or 22 wherein the mechanosensitive ion channel is a mechanosensitive Ca^{2+} -permeable (MscCa) channel.

24. The method of claim 20, 21, or 22 wherein the agent is a polypeptide comprising an amino acid sequence comprising at least 90% identity to SEQ ID NO: 1 or to SEQ ID NO: 7.

25. The method of claim 24 wherein the agent is a polypeptide comprising SEQ ID NO: or ~~1~~ SEQ ID NO: 7.

26. The method of claim 24 wherein the agent is a polypeptide comprising SEQ ID NO: 1 or SEQ ID NO: 7.

27. The method of claim 26 wherein the antibody binds to an epitope present on SEQ ID NO: 5 or SEQ ID NO: 6.

28. The method of claim 23 wherein the MscCa channel comprises an MscCa polypeptide, and wherein the agent is a polynucleotide that decreases expression of the MscCa polypeptide.

29. The method of claim 20, 21, or 22 wherein the cancer is prostate cancer, breast cancer, colon cancer, lung cancer, bladder cancer, ovary cancer, pancreas cancer, or skin cancer.

30. The method of claim 23 wherein the agent decreases activity of an MscCa channel comprising a polypeptide comprising SEQ ID NO: 2.

31. A method for inhibiting expression of an MscCa polypeptide comprising:

administering into a cell an effective amount of an RNA polynucleotide, wherein the polynucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises a nucleotide sequence of between 16 and 30 nucleotides, wherein the nucleotide sequence is substantially identical to consecutive nucleotides of an mRNA encoding a polypeptide of SEQ ID NO: 2, and wherein the cell comprising the RNA polynucleotide has decreased MscCa activity, decreased motility, decrease invasiveness, or a combination thereof, when compared to a control cell that does not comprise the RNS polynucleotide.

32. A method for treating cancer comprising:

administering to a subject having cancer an effective amount of an RNA polynucleotide, wherein the polynucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprise a nucleotide sequence of between 16 and 30 nucleotides, wherein the nucleotide sequence is substantially identical to consecutive nucleotides of an mRNA encoding a polypeptide of SEQ ID NO: 2, and wherein a symptom of the cancer is decreased.

33. A method for decreasing metastasis of a cancer cell comprising:

administering to a subject at risk of developing cancer an effective amount of an RNA polynucleotide, wherein the polynucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises a nucleotide sequence of between 16 and 30 nucleotides, and wherein the nucleotide sequence is substantially identical to consecutive nucleotides of an mRNA encoding a polypeptide of SEQ ID NO: 2.

34. A method for decreasing a symptom associated with cancer comprising:

administering to a subject having cancer an effective amount of an RNA polynucleotide, wherein the polynucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises a nucleotide sequence of between 16 and 30 nucleotides, wherein the nucleotide sequence is substantially identical to consecutive nucleotides of an mRNA encoding a polypeptide of SEQ ID NO: 2.

* * * * *

RECEIVED
CENTRAL FAX CENTER

SEP 7 - 2007

APPLICATION DATA SHEET

APPLICATION INFORMATION

Application Type:: REGULAR
Subject Matter:: UTILITY
CD-ROM or CD-R?:: NONE
Title:: MECHANOSENSITIVE ION CHANNELS
And METHODS OF USE
Attorney Docket Number:: 265.00450101
Small Entity?:: YES

INVENTOR INFORMATION

Applicant Authority Type:: INVENTOR
Primary Citizenship Country:: US
Status:: FULL CAPACITY
Given Name:: Owen
Middle Name:: P.
Family Name:: HAMILL
City of Residence:: Galveston
State or Province of Residence:: Texas
Country of Residence:: US
Street of Mailing Address:: 1212 Winnie Street
City of Mailing Address:: Galveston
State or Province of Mailing Address:: Texas
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 77550

Applicant Authority Type:: INVENTOR
Primary Citizenship Country:: Spain
Status:: FULL CAPACITY
Given Name:: Rosario
Family Name:: Maroto
City of Residence:: Galveston
State or Province of Residence:: Texas
Country of Residence:: US
Street of Mailing Address:: 1212 Winnie Street
City of Mailing Address:: Galveston
State or Province of Mailing Address:: Texas
Country of Mailing Address:: US
Postal or Zip Code of Mailing Address:: 77550

WO 2005/070122

PCT/US2005/000722

10. The method of claim 1 wherein the treated cell has increased apoptosis compared to the control cell.

11. An agent identified by the method of claim 1.

12. A method for identifying an agent that decreases a phenotype of a cell comprising:

contacting a cell expressing an MscCa channel with a candidate agent to yield a treated cell; and

comparing the phenotype of the treated cell with the phenotype of a control cell not contacted with the candidate agent, wherein the phenotype is selected from the group of motility, invasiveness, proliferation, and a combination thereof, and wherein a decreased phenotype for the treated cell indicates the candidate agent decreases the phenotype.

13. The method of claim 12 wherein the candidate agent causes activity of an MscCa channel of the treated cell to decrease.

14. The method of claim 12 wherein the MscCa channel comprises a polypeptide comprising an amino acid sequence of at least 90% identity to SEQ ID NO: 2, wherein the polypeptide has MscCa activity.

15. The method of claim 14 wherein the MscCa channel comprises a polypeptide comprising SEQ ID NO: 2.

16. The method of claim 12 wherein the cell is a tumor cell.

17. The method of claim 12 wherein the cell is a human prostate tumor cell line.

18. The method of claim 17 wherein the human prostate tumor cell line is ATCC CRL-1435.

19. An agent identified by the method of claim 12.

WO 2005/070122

PCT/US2005/000722

20. A method for treating cancer comprising:
administering to a subject having cancer an effective amount of a composition comprising an agent that decreases activity of a mechanosensitive ion channel present on a cancer cell, wherein a symptom of the cancer is decreased.
21. A method for decreasing metastasis of a cancer cell comprising:
administering to a subject at risk of developing cancer an effective amount of a composition comprising an agent that decreases activity of a mechanosensitive ion channel.
22. A method for decreasing a symptom associated with cancer comprising:
administering to a subject having cancer an effective amount of a composition comprising an agent that decreases activity of a mechanosensitive ion channel.
23. The method of claim 20, 21, or 22 wherein the mechanosensitive ion channel is a mechanosensitive Ca^{2+} -permeable (MscCa) channel.
24. The method of claim 20, 21, or 22 wherein the agent is a polypeptide comprising an amino acid sequence comprising at least 90% identity to SEQ ID NO:1 or to SEQ ID NO:7.
25. The method of claim 24 wherein the agent is a polypeptide comprising SEQ ID NO:1 or SEQ ID NO:7.
26. The method of claim 23 wherein the agent is an antibody that specifically binds an MscCa polypeptide.
27. The method of claim 26 wherein the antibody binds to an epitope present on SEQ ID NO:5 or SEQ ID NO:6.

WO 2005/070122

PCT/US2005/000722

28. The method of claim 23 wherein the MscCa channel comprises an MscCa polypeptide, and wherein the agent is a polynucleotide that decreases expression of the MscCa polypeptide.

29. The method of claim 20, 21, or 22 wherein the cancer is prostate cancer, breast cancer, colon cancer, lung cancer, bladder cancer, ovary cancer, pancreas cancer, or skin cancer.

30. The method of claim 23 wherein the agent decreases activity of an MscCa channel comprising a polypeptide comprising SEQ ID NO: 2.

31. A method for inhibiting expression of an MscCa polypeptide comprising:

administering into a cell an effective amount of an RNA polynucleotide, wherein the polynucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises a nucleotide sequence of between 16 and 30 nucleotides, wherein the nucleotide sequence is substantially identical to consecutive nucleotides of an mRNA encoding a polypeptide of SEQ ID NO:2, and wherein the cell comprising the RNA polynucleotide has decreased MscCa activity, decreased motility, decreased invasiveness, or a combination thereof, when compared to a control cell that does not comprise the RNA polynucleotide.

32. A method for treating cancer comprising:

administering to a subject having cancer an effective amount of an RNA polynucleotide, wherein the polynucleotide comprises a sense strand and an antisense strand, wherein the sense strand comprises a nucleotide sequence of between 16 and 30 nucleotides, wherein the nucleotide sequence is substantially identical to consecutive nucleotides of an mRNA encoding a polypeptide of SEQ ID NO:2, and wherein a symptom of the cancer is decreased.

33. A method for decreasing metastasis of a cancer cell comprising:

administering to a subject at risk of developing cancer an effective amount of an RNA polynucleotide, wherein the polynucleotide comprises a sense strand